Wedbush Starts Insmed (INSM) at Outperform; Anticipate Upcoming Catalysts
Tweet
Share
E-mailGet Alerts INSM Hot Sheet
Price: $24.11 --0%
Rating Summary:
24 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 2
Rating Summary:
24 Buy, 2 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 6 | Down: 4 | New: 2
Join SI Premium – FREE
Wedbush initiates coverage on Insmed (NASDAQ: INSM) with a Outperform. PT $15.00.
Wedbush analyst says, "We expect the FDA will lift the clinical hold on Insmed’s Phase III studies of ARIKACE in cystic fibrosis (CF) and Nontuberculous mycobacteria (NTM) settings...ARIKACE is a liposomal formulation of amikacin designed for nebulization and inhalation...ARIKACE is ready to enter Phase III studies for the management of chronic Pseudomonas infections in patients with CF (a $300-million worldwide opportunity) and the rare but serious NTM setting (a $250-million worldwide opportunity)."
"We anticipate that upcoming catalysts for INSM will include the FDA’s response to Insmed’s safety-data submission and lifting of the clinical hold in late September/early October and initiation of three PIII trials in Q4:11/Q1:12."
For more ratings news on Insmed click here and for the rating history of Insmed click here.
Shares of Insmed closed at $4.48 yesterday.
Wedbush analyst says, "We expect the FDA will lift the clinical hold on Insmed’s Phase III studies of ARIKACE in cystic fibrosis (CF) and Nontuberculous mycobacteria (NTM) settings...ARIKACE is a liposomal formulation of amikacin designed for nebulization and inhalation...ARIKACE is ready to enter Phase III studies for the management of chronic Pseudomonas infections in patients with CF (a $300-million worldwide opportunity) and the rare but serious NTM setting (a $250-million worldwide opportunity)."
"We anticipate that upcoming catalysts for INSM will include the FDA’s response to Insmed’s safety-data submission and lifting of the clinical hold in late September/early October and initiation of three PIII trials in Q4:11/Q1:12."
For more ratings news on Insmed click here and for the rating history of Insmed click here.
Shares of Insmed closed at $4.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Loop Capital Starts MongoDB (MDB) at Buy, '2H Ramp Ahead'
- JPMorgan Upgrades Roblox Corp. (RBLX) to Overweight
- BofA Securities Reinstates Mahanagar Gas Limited (MAHGL:IN) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
